Teva launches generic Lamictal tablets in US

Jul 23, 2008 (Datamonitor via COMTEX) -- TEVA | Quote | Chart | News | PowerRating -- Teva Pharmaceutical Industries has started the commercial shipment of its generic version of Lamictal tablets, 25mg, 100mg, 150mg and 200mg in the US.

Teva's Lamotrigine tablets are the AB-rated generic equivalent of GlaxoSmithKline's Lamictal tablets, and are indicated as adjunctive therapy in the treatment of partial seizures and the generalized seizures of Lennox-Gastaut syndrome, for conversion to monotherapy in adults with partial seizures who are taking certain other antiepileptic agents, and for maintenance treatment of bipolar I disorder.

Previously GlaxoSmithKline and Teva entered into an agreement to settle patent litigation under which GlaxoSmithKline granted Teva the exclusive right to manufacture and sell a generic version of Lamictal during the six-month pediatric exclusivity which ends on January 22, 2009.

http://www.datamonitor.com

Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

Morning Coffee with TradingMarkets -- Free Newsletter

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index